| Grant Title | Grantor | Amount | Award Date |
|---|
| Abby R. Rosenberg, MD | Fellow Award | St. Baldrick's Foundation | | July 1, 2012 - June 30, 2014 |
| Abby R. Rosenberg, MD | Clinical Research Scholar | Seattle Children's Hospital Research Institute | | July 1, 2012 - June 30, 2014 |
| Rebecca A. Gardner, MD | A phase 1 trial of autologous T cells genetically modified to express a CD19 specific chimeric antigen receptor to treat pediatric relapsed acute lymphoblastic leukemia | SCRI-CCTR Clinical Research Scholar Program | | May 2012 - May 2014 |
| Rebecca A. Gardner, MD | Autologous T cells Modified to Target CD19+ Pediatric ALL | Rally Foundation | | May 2012 - May 2013 |
| Abby R. Rosenberg, MD | Young Investigator Award | Conquer Cancer Foundation | | 2012 - 2013 |
| Eric J. Chow, MD, MPH | Determinants of late cardiovascular morbidity among survivors of hematopoietic cell transplantation | National Cancer Institute | | Aug. 1, 2011 - July 30, 2016 |
| Rebecca A. Gardner, MD | Engineering a Graft Versus Leukemia Effect into Cord Blood Transplant | Alex's Lemonade Stand | | July 2011 - Sept. 2013 |
| Phoenix Ho | SHIP and WT1 alterations as markers of PI3K/Akt activation in pediatric AML | Mary Claire Satterly Foundation |
$50,000.00 | Nov. 1, 2010 |
| Dana Matthews, MD | Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia | National Institutes of Health | | Sept. 30, 2010 |
| Scott John Diede, MD, PhD | The Role of DNA Methylation in Normal Muscle Development and Pediatric Rhabdomyosarcoma | Hyundai Hope on Wheels |
$60,000 | Aug. 1, 2010 - July 31, 2011 |
| Scott John Diede, MD, PhD | The Role of DNA Methylation in Pediatric Cancer | St. Baldrick's Foundation |
$110,000/year | July 1, 2010 - June 30, 2013 |
| Scott John Diede, MD, PhD | The Role of DNA Methylation in Pediatric Cancer | Alex's Lemonade Stand Foundation for Cancer Research |
$40,000/year | July 1, 2010 - June 30, 2012 |
| Scott John Diede, MD, PhD | The Role of DNA Methylation in Pediatric Medulloblastoma | American Brain Tumor Association |
$40,000/year | July 1, 2010 - June 30, 2012 |
| Phoenix Ho, MD | Implications of s-SHIP Expression and SHIP Alterations in AML | American Society of Clinical Oncology Cancer Foundation |
$50,000.00 | July 1, 2009 |
| Phoenix Ho, MD | Implications of s-SHIP Expression and SHIP Alterations in AML | University of Washington Child Health Research Center |
$240,000.00 | July 1, 2009 |
| Douglas Hawkins, MD | Children’s Oncology Group trial AEWS0531 | NIH |
$11,956.00 | March 1, 2009 |
| Douglas Hawkins, MD | Children’s Oncology Group trial AEWS0331 | NIH |
$11,956.00 | March 1, 2009 |
| Douglas Hawkins, MD | Children’s Oncology Group Soft Tissue Sarcoma Committee Chair | NIH |
$23.913.00 | March 1, 2009 |
| Douglas Hawkins, MD | Children’s Oncology Group- cooperative group trial, Institutional Principal | NIH |
$57,390.00 | March 1, 2009 |
| Julie Park, MD | NIH-U10 CA098543-05 | NIH | | Feb. 28, 2009 |
| Michael Bender, MD | Northwest Sickle Cell Collaborative | Washington State Department of Health |
$100,000.00 | Jan. 1, 2009 |
| Michael Bender, MD | Newborn Screening Program | Washington State Department of Health |
$3,299.00 | Jan. 1, 2009 |
| Michael Bender, MD | Washington State Sickle Cell Contract | Washington State Department of Health |
$46,183.00 | Jan. 1, 2009 |
| Michael Bender, MD | Towards a Canine Model of Fanconi Anemia | NIH / NHLBI |
$28,328.00 | Jan. 1, 2009 |
| Michael Bender, MD | Digital DNaseI mapping and footprinting of the mouse genome | NIH |
$89,413.00 | Jan. 1, 2009 |
| Paul Carpenter, MD | Unknown | BMT CTN Protocol 0801 | | Jan. 1, 2009 |
| Rebecca Johnson, MD | CHRMC Teen Cancer Program | • Children’s Hospital Guild Association |
$1,500,000.00 | Jan. 1, 2009 |
| Rebecca Johnson, MD | Gene expression signature as a predictor of “young adult type” breast cancer: a retrospective analysis of AYA data | • Lance Armstrong Foundation |
$45,000.00 | Jan. 1, 2009 |
| Eric Chow, MD, MPH | Glucocorticoid pharmacogenetics and obesity after childhood ALL therapy | Center for Clinical & Translational Research Pediatric Pilot Award | | Dec. 1, 2008 |
| Eric Chow, MD, MPH | Unrestricted funds for research support | Hyundai Hope on Wheels Cancer Research Scholarship | | Oct. 1, 2008 |
| K Baker, MD, MS | Abdominal aorta intima-media thickness: a measure of early subclinical atherosclerosis | Minnesota Medical Foundation |
$12,000.00 | Aug. 15, 2008 |
| Eric Chow, MD, MPH | Glucocorticoid pharmacogenetics and obesity after childhood ALL therapy | Leukemia & Lymphoma Society | | July 1, 2008 |
| Eric Chow, MD, MPH | Late cardiovascular morbidity and mortality after allogeneic hematopoietic cell transplantation - a population-based analysis | ASBMT |
$unknown | July 1, 2008 |
| Scott John Diede, MD, PhD | DNA Palindrome Formation Promotes Genomic Instability in Cancer | University of Washington Child Health Research Center |
$75,000/year | July 1, 2008 - June 30, 2011 |
| Scott John Diede, MD, PhD | DNA Palindrome Formation Promotes Genomic Instability in Cancer | American Society of Clinical Oncology |
$50,000 | July 1, 2008 - June 30, 2009 |
| Douglas Hawkins, MD | Children’s Oncology Group trial AEWS0531 | NIH |
$13,995.00 | March 1, 2008 |
| Douglas Hawkins, MD | Children’s Oncology Group trial AEWS0331 | NIH |
$11,663.00 | March 1, 2008 |
| Douglas Hawkins, MD | Children’s Oncology Group- cooperative group trial | NIH |
$55,980 .00 | March 1, 2008 |
| Paul Carpenter, MD | Unknown | Osiris Therapeutics, Inc | | Jan. 1, 2008 |
| Paul Carpenter, MD | Unknown | Novartis Pharmaceuticals Corp | | Jan. 1, 2008 |
| Jessica Pollard, MD | Heterogeneity of CD33 expression in pediatric AML and its | For JulieFoundation | | Jan. 1, 2008 |
| Jessica Pollard, MD | Heterogeneity of CD33 expression in pediatric AML and its | CureSearch Research Fellowship Award | | Jan. 1, 2008 |
| Jessica Pollard, MD | Heterogeneity of CD33 expression in pediatric AML and its | St. Baldrick’s Foundation, Career Development | | Jan. 1, 2008 |
| Julie Park, MD | NIH-U10 CA97452-05 | NIH | | Aug. 1, 2007 |
| Julie Park, MD | NIH-U10 CA97452-05 | NIH | | Aug. 1, 2007 |
| Eric Chow, MD, MPH | A pilot study to determine the prevalence, risk factors, and biomarkers associated with the metabolic syndrome in childhood acute lymphoblastic leukemia survivors, comparing conventional treatment with hematopoietic cell transplantation | ASCO/Lance Armstrong Foundation |
$unknown | July 2, 2007 |
| Julie Park, MD | Translation Research for Pediatric Solid Tumors | Alex’s Lemonade Stand Foundation |
$200,000.00 | July 1, 2007 |
| K Baker, MD, MS | Gene Therapy for Purine Nucleoside Phosphorylase Deficiency (PNP) | NIAID |
$75,000.00 | May 1, 2007 |
| Ann Woolfrey, MD | Adult Leukemia Research Center | NIH NCI |
$242,509.00 | March 1, 2007 |
| Julie Park, MD | Phase I-II Safety & Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed-Refractory Solid Tumors | Wyeth Pharmaceuticals | | Jan. 17, 2007 |
| Ann Woolfrey, MD | Sub-Project- BMT0201 | NCI NHLBI | | Oct. 1, 2006 |
| K Baker, MD, MS | Metabolic Syndrome Following Transplant for Leukemia | NIH/NCI |
$1,497,680.00 | Aug. 15, 2006 |
| Ann Woolfrey, MD | Stem Cell Transplantation- Basic Clinical Research | NIH/NHLBI |
$93,800.00 | Aug. 1, 2006 |
| Ann Woolfrey, MD | Gene Therapy for Fanconi Anemia | NIH |
$479,927.00 | July 24, 2006 |
| Julie Park, MD | NIH – Biology and Therapy of High Risk Neuroblastoma | NIH | | June 30, 2006 |
| K Baker, MD, MS | Metabolic Syndrome in Childhood Cancer Survivors | NIH/NCI |
$2,317,865.00 | April 1, 2006 |
| K Baker, MD, MS | FHCRC Survivorship Program | Lance Armstrong Foundation |
$1,700,054.00 | Jan. 1, 2006 |
| Eric Chow, MD, MPH | Childhood Cancer Survivor Study is an NCI-funded resource study whose primary goal is to study the late effects among a cohort of childhood cancer survivors | NCI |
$unknown | Dec. 1, 2005 |
| Julie Park, MD | Genetic Predisposition to Chemotherapy Toxicity in Children Receiving Cyclophosphamide | CHRMC Gift Income Genetic Predisposition to Chemotherapy Toxicity in Children Receiving Cyclophosphamide Endowment | | Oct. 1, 2005 |
| K Baker, MD, MS | Pediatric Cancer Epidemiology Training Grant | National Institutes of Health |
$1,115,934.00 | Sept. 30, 2004 |
| Michael Bender, MD | Maintenance of gene expression in the red cell lineage | NIH/NHLBI |
$545,338.00 | Sept. 15 |
| Julie Park, MD | NIH-U10 CA098543-05 | NIH | | Feb. 28 |
| Julie Park, MD | Targeted Hematopoietic Irradiation for Treatment of High Risk Neuroblastoma | 7. CHRMC Gift Income Targeted Hematopoietic Irradiation for Treatment of High Risk Neuroblastoma Endowment | | Dec. 1, 1999 |
| Douglas Hawkins, MD | Acute Lymphoblastic Leukemia Research | Orrico Foundation |
$333,109.00 | Feb. 1, 1997 |
| Douglas Hawkins, MD | Pilot Study of VACIME with Peripheral Blood Progenitor Cells and Neupogen for Patients with Metastatic Sarcoma at Diagnosis, Phase I Study of Thiotepa in Combination with Fixed Doses of Carboplatin and Topotecan for Children with Recurrent or Refractory Solid Tumorsk 166Ho-DOTMP as Targeted Radiotherapy for Recurrent or Refractory Ewing’s Sarcoma , Establishing Xenografts from Primary Pediatric Bone Sarcomas | Gilbertson Foundation |
$158,150.00 | Sept. 1, 1996 |
| Michael Bender, MD | Function of Human & Mouse b-Globin Locus Control Regions | NIH/NIDDK |
$378,285.00 | April 1, 1992 |
| | | | |
| Ronald Se-Yuen Cheung, MD, PhD | University of Washington Child Health Research Center | NIH | | |
| Brandon K. Hadland, MD, PhD | K12 CA076930 Career Development in Pediatric and Medical Oncology | NIH | | |